GURUFOCUS.COM » STOCK LIST » Europe » Germany » HAM » Biogen Inc (HAM:IDP) » Definitions » Change In Payables And Accrued Expense
Switch to:

Biogen (HAM:IDP) Change In Payables And Accrued Expense

: €-180 Mil (TTM As of Dec. 2023)
View and export this data going back to 2001. Start your Free Trial

Biogen's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was €-454 Mil. It means Biogen's Accounts Payable & Accrued Expense declined by €454 Mil from Sep. 2023 to Dec. 2023 .

Biogen's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was €-185 Mil. It means Biogen's Accounts Payable & Accrued Expense declined by €185 Mil from Dec. 2022 to Dec. 2023 .


Biogen Change In Payables And Accrued Expense Historical Data

The historical data trend for Biogen's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Payables And Accrued Expense
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 216.18 126.75 -84.43 -107.05 -184.87

Biogen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Change In Payables And Accrued Expense Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -703.94 -275.53 154.97 394.48 -454.37

Biogen Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-180 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Biogen's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (HAM:IDP) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (HAM:IDP) » Definitions » Change In Payables And Accrued Expense
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (HAM:IDP) Headlines

No Headlines